Company: IMNN
Filing Date: 2025-05-13
Form Type: S-1/A
Source: 0001641172-25-009814
Chunk: 36

Company: Imunon, Inc.
Filing Date: 2025-05-13
Form: S-1/A
Chunk 36
---
 beginning on the Initial Exercise Date (i.e., the date on which we file a Current Report on Form 8-K with the SEC giving public notice of Stockholder Approval)and will expire two and one-half (2.5) years after the Initial Exercise Date. The exercise price of the common warrants and the number of shares underlying the common warrants are subject to adjustment, including in the following instances:

| ● | Recapitalization                                                                             
 and Other Events: The exercise prices of the common warrants and number of shares underlying 
 the common warrants are subject to adjustment for stock splits, dividends, combinations,     
 recapitalization and similar events.                                                         |

| ● | Adjustment                                                                                         
 at the “Adjustment Date”: On the Adjustment Date (as defined below), the                           
 exercise price of the common warrants will be reduced (but in no event increased) to the           
 greater of (i) the Floor Price (as defined below) and (ii) the lowest daily dollar volume-weighted 
 average price during the period beginning two full trading days prior to the Adjustment Date       
 and ending on the 10th trading day after the Adjustment Date. Upon any such resulting adjustment   
 of the exercise price of the common warrants, the number of shares of Common Stock issuable        
 under the common warrants will be increased such that the aggregate exercise price of a common     
 warrant (adjusted for any exercises by a holder prior to this adjustment) will remain unchanged    
 following such adjustment. No adjustment in connection with an Adjustment Date or otherwise        
 may result in an adjustment of the exercise price to a price less than the Floor Price. As         
 a result, the aggregate number of shares of Common Stock underlying all of the common warrants     
 may increase from 15,000,000 up to 150,000,000 (in each case, based on an assumed public offering  
 price of $0.80 per share), assuming full adjustment of the exercise price to the Floor Price       
 and before giving effect to the “alternative cashless exercise” provision. Assuming                
 full adjustment of the exercise price to the Floor Price, the aggregate number of shares           
 of Common Stock issuable upon the exercise of all of the common warrants pursuant to the           
 “alternative cashless exercise” provisions therein would be 450,000,000 (based                     
 on an assumed public offering price of $0.80 per share).                                           |
| ● | Adjustments                                                                                        
 for Reverse Splits and Share Combination Events: If at any time during the term of the             
 common warrants there occurs any stock split,